Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences has demonstrated expanding operating margins, reflecting a well-aligned growth strategy targeting approximately 10% annual sales growth, with expected earnings per share leverage from its diverse structural heart therapy portfolio. Recent physician surveys indicate increased procedure volumes for transcatheter aortic valve replacement (TAVR) driven by improved hospital capacity and flexibility, which could lead to accelerated growth in the TAVR segment. Additionally, the launch of the Cordella heart failure monitoring device and the expectation of strong real-world outcomes from the EVOQUE and mitral therapy products bolster the company’s growth prospects.

Edwards Lifesciences faces significant headwinds in its TAVR business growth outlook, which may be lower than investor expectations due to a potentially smaller total addressable market. The company's innovation pipeline for minimally invasive tricuspid and mitral valve technologies is likely to experience delays, adversely impacting revenue contributions. Additionally, the challenging global regulatory and reimbursement environment, along with increased competition and macroeconomic factors, are projected to further constrain revenue growth, prompting a cautious outlook on the stock.